“Pfizer Halts Enrollment In Lung-Cancer Drug Trial” (Wall Street Journal)
Pfizer Inc. (PFE) has temporarily halted enrollment of new patients in a clinical trial of an experimental lung-cancer drug, saying the drug was associated with a higher rate of adverse events, including fatalities, than those who didn’t get the drug.
“J&J wheels and deals, awaits new product approvals” (Business Week)
Johnson & Johnson, the world’s biggest healthcare company and a Dow Jones industrial average component, reports earnings for the third quarter Tuesday morning. Here’s a summary of key developments and analyst opinion related to the period.
“Acorda shares plunge on negative FDA review”(AP)
Shares of Acorda Therapeutics plummeted Friday after the Food and Drug Administration issued a negative opinion that questioned the safety and effectiveness of the company’s multiple sclerosis drug.
Shares of Seattle-based Omeros, the first true U.S. biotech company to go public in more than 18 months, dropped about 13 percent in the company’s first day of trading.
SUBSCRIBE